Patent Number US8158416 B2 2012-04-17
 
Process for the production of infectious negative-strand RNA viruses
The present invention relates, in general, to a methodology for the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA).Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications.The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses.Measles virus (MV) is used as a model for other representatives of the Mononegavirales, in particular the family Paramyxoviridae.

 ©Questel
FamPat family
Publication Number Type Publi.Date Links
  EP0780475 A1 1997-06-25
STG: (A1) Application published with search report
AP: 1995EP-0112559
  EP0780475 B1 1999-06-09
STG: (B1) Patent specification
AP: 1995EP-0112559
  EP0780475 B2 2006-07-19
STG: (B2) New patent specification
AP: 1995EP-0112559
  EP0846181 A1 1998-06-10
STG: (A1) Application published with search report
AP: 1996EP-0928446
  EP0846181 B1 2005-03-02
STG: (B1) Patent specification
AP: 1996EP-0928446
  EP0846181 B2 2013-12-11
STG: (B2) New patent specification
AP: 1996EP-0928446
  US20070280961 A1 2007-12-06
STG: (A1) Application published
AP: 2005US-11320487
  US7851214 B2 2010-12-14
STG: (B2) Granted patent as second publication
AP: 2005US-11320487
  US20080124803 A1 2008-05-29
STG: (A1) Application published
AP: 2007US-11899492
  US7993924 B2 2011-08-09
STG: (B2) Granted patent as second publication
AP: 2007US-11899492
  US7402429 B1 2008-07-22
STG: (B1) Granted patent as first publication
AP: 1996US-09011425
  US20120003264 A1 2012-01-05
STG: (A1) Application published
AP: 2011US-13175307
  US8158416 B2 2012-04-17
STG: (B2) Granted patent as second publication
AP: 2011US-13175307
PCT  WO97/06270 A1 1997-02-20
STG: (A1) Published application with search report
AP: 1996WO-EP03544
  DE69510207 D1 1999-07-15
STG: (D1) Grant (no unexamined application published) patent law 81
AP: 1995DE-6010207
  DE69510207 T2 2000-03-23
STG: (T2) Trans. of EP patent
AP: 1995DE-6010207
  DE69510207 T3 2007-02-15
STG: (T3) Trans. of EP patent after opposition
AP: 1995DE-6010207
  DE69634407 D1 2005-04-07
STG: (D1) Grant (no unexamined application published) patent law 81
AP: 1996DE-6034407
  DE69634407 T2 2005-12-29
STG: (T2) Trans. of EP patent
AP: 1996DE-6034407
  DE69634407 T3 2014-05-22
STG: (T3) Trans. of EP patent after opposition
AP: 1996DE-6034407
  CA2228956 A1 1997-02-20
STG: (A1) Application laid open
AP: 1996CA-2228956
  CA2228956 C 2006-07-04
STG: (C) Patent (second level)
AP: 1996CA-2228956
  AU6820896 A 1997-03-05
STG: (A) Open to public inspection
AP: 1996AU-0068208
  AU721202 B2 2000-06-29
STG: (B2) Patent preceeded by A1
AP: 1996AU-0068208
  ATE181112 T1 1999-06-15
STG: (T1) Translation of an European patent specification
AP: 1995AT-0112559T
  DK0780475 T3 1999-11-15
STG: (T3) Translation of EP patent
AP: 1995DK-0112559
  DK0780475 T4 2006-10-23
STG: (T4) Translation of amended EP patent
AP: 1995DK-0112559
  ATE290092 T1 2005-03-15
STG: (T1) Translation of an European patent specification
AP: 1996AT-0928446T
  DK0846181 T3 2005-07-04
STG: (T3) Translation of EP patent
AP: 1996DK-0928446
  DK0846181 T4 2014-02-10
STG: (T4) Translation of amended EP patent
AP: 1996DK-0928446
  PT846181 E 2005-07-29
STG: (E) Availability of national translation of European patent
AP: 1996PT-0928446T
  ES2239336 T3 2005-09-16
STG: (T3) Translation of granted European patent (former B3)
AP: 1996ES-0928446T
  ES2239336 T5 2014-03-19
STG: (T5) Translation of modified European patent from 1996
AP: 1996ES-0928446T
First Date of Grant 1999-06-09
2005-03-02
2008-07-22
2010-12-14
2011-08-09
2012-04-17
1999-07-15
2005-04-07
2000-06-29
1999-06-15
2005-03-15
2005-07-29
2006-07-04
1999-11-15
2005-07-04
2005-09-16
Inventor BILLETER MARTIN A
SPIELHOFER PIUS
KAELIN KARIN
RADECKE FRANK
SCHNEIDER HENRIETTE
All applicant/assignee SCHWEIZ. SERUM- & IMPFINSTITUTBERN ([CH])
SCHWEIZ. SERUM- & IMPFINSTITUTBERN ([CH])
SCHWEIZ. SERUM- & IMPFINSTITUT BERN ([CH])
SCHWEIZ. SERUM- & IMPFINSTITUT BERN ([CH])
Crucell Switzerland AG ([CH])
Crucell Switzerland AG ([CH])
Schweiz Serum & Impfinstitut Bern ([CH])
Schweiz. Serum & Impfinstitut Bern ([CH])
Crucell Switzerland AG ([CH])
Crucell Holland B.V. ([NL])
Crucell Switzerland AG ([CH])
CRUCELL SWITZERLAND AG ([CH])
Crucell Switzerland AG ([CH])
SCHWEIZ. SERUM- & IMPFINSTITUT BERN ([CH])
SCHWEIZ. SERUM- & IMPFINSTITUT BERN, BERN, CH
SCHWEIZ. SERUM- & IMPFINSTITUT BERN, BERN
Schweiz. Serum- & Impfinstitut Bern ([CH])
SCHWEIZ. SERUM- & IMPFINSTITUT BERN, BERN
Schweiz. Serum- & Impfinstitut Bern ([CH])
CRUCELL SWITZERLAND AG ([CH])
SCHWEIZ. SERUM- & IMPFINSTITUT BERN
SCHWEIZ. SERUM- & IMPFINSTITUT BERN
SCHWEIZ. SERUM- & IMPFINSTITUT BERN
SCHWEIZ. SERUM- & IMPFINSTITUT BERN
SCHWEIZ. SERUM - & IMPFINSTITUT BERN
SCHWEIZ SERUM- & IMPFINSTITUT BERN ([CH])
SCHWEIZ. SERUM- & IMPFINSTITUT BERN ([CH])
SCHWEIZ. SERUM- & IMPFINSTITUT BERN
SCHWEIZ. SERUM- & IMPFINSTITUT BERN
SCHWEIZ. SERUM- & IMPFINSTITUT BERN
CRUCELL SWITZERLAND AG
SCHWEIZ. SERUM- & IMPFINSTITUT BERN
CRUCELL SWITZERLAND AG
Priority Details 1995EP-0112559 1995-08-091996EP-0928446 1996-08-091996US-09011425 1998-09-151996WO-EP03544 1996-08-092005US-11320487 2005-12-272007US-11899492 2007-09-062011US-13175307 2011-07-01
Designated States Contracting States: AT CH DE DK FR GB IT LI NL SE
Contracting States: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
National States: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN
ARIPO: KE LS MW SD SZ UG
EPO: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
OAPI: BF BJ CF CG CI CM GA
   
©Questel